| Not Yet Recruiting | A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis Psoriasis | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | Mass Balance Study of [14C] D-2570 Mass Balance Study | Phase 1 | 2026-03-04 |
| Not Yet Recruiting | A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) Active Systemic Lupus Erythematosus | Phase 2 | 2026-01-15 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque P Plaque Psoriasis | Phase 3 | 2026-01-13 |
| Recruiting | A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis PsA (Psoriatic Arthritis) | Phase 2 | 2025-12-22 |
| Recruiting | Healthy Volunteer Study Healthy Volunteer | Phase 1 | 2025-12-04 |
| Recruiting | Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis Plaque Psoriasis | Phase 3 | 2025-09-18 |
| Recruiting | A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis | Phase 2 | 2025-05-22 |
| Completed | Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D- Healthy | Phase 1 | 2024-08-13 |
| Completed | Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2024-01-31 |
| Completed | Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects Mass Balance Study | Phase 1 | 2023-12-08 |
| Completed | A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Healthy Male | Phase 1 | 2023-05-24 |
| Active Not Recruiting | Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout Gout | Phase 2 | 2023-04-17 |
| Active Not Recruiting | Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2022-10-12 |
| Completed | Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients Hyperuricemia | Phase 2 | 2022-09-28 |
| Recruiting | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer Breast Cancer | Phase 3 | 2022-09-15 |
| Terminated | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer NSCLC | Phase 1 / Phase 2 | 2022-09-13 |
| Completed | Study in Healthy Adult Female Subjects Mass Balance Recovery | Phase 1 | 2022-03-29 |
| Completed | Evaluation of PK and Safety of D-0120 and Allopurinol Healthy | EARLY_Phase 1 | 2021-11-01 |
| Completed | Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects Healthy Female Volunteer | Phase 1 | 2021-10-27 |
| Completed | Study to Evaluate D-1553 in Subjects With Lung Cancer NSCLC | Phase 1 / Phase 2 | 2021-03-16 |
| Active Not Recruiting | Study to Evaluate D-1553 in Subjects With Solid Tumors Solid Tumor, Adult, NSCLC, CRC | Phase 1 / Phase 2 | 2020-10-02 |
| Completed | Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers Healthy Volunteers | Phase 1 | 2019-09-18 |
| Completed | D-0120 Safety and PK/PD Study in China Hyperuricemia or Gout | Phase 1 / Phase 2 | 2019-04-18 |
| Completed | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer Solid Tumor, NSCLC, EGFR T790M | Phase 2 | 2019-02-28 |
| Completed | Food Effect Study of D-0502 Tablet in Healthy Volunteers Breast Cancer | Phase 1 | 2018-10-23 |
| Completed | A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastati Breast Cancer | Phase 1 | 2018-03-18 |
| Completed | D-0316 First Time in Patients Ascending Dose Study Advanced Non Small Cell Lung Cancer | Phase 1 | 2018-01-03 |
| Completed | D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers Gout | Phase 1 | 2017-09-13 |